BRC hIPSC Core Facility
The Cambridge Biomedical Centre (BRC) hIPSCs core facility was created in 2009 to promote the clinical applications of human Induced Pluripotent Stem Cells (hIPSCs) and to answer the increasing need for deriving new lines for disease modelling in vitro. During the past two years, this platform, unique in Europe, has derived and characterised more the 400 hIPSC lines from 70 patients suffering from neurodegenerative diseases, cardiovascular syndromes, metabolic and blood disorders. These projects have been directed by clinicians associated with diverse departments of University of Cambridge, including Neurosciences, Metabolic Science, Cardiovascular Medicine, Haematology, Surgery and Hepatology/Thoracic Medicine.
The main objective of this platform is the production of hIPSC lines on demand for the development of in vitro models of disease, compatible with drug development and basic mechanistic studies. In addition, a growing activity of the BRC hIPSCs core facility will be in training clinicians and basic scientists to derive, grow and differentiate hIPSC lines. Located in the Anne McLaren Laboratory for Regenerative Medicine (LRM), the BRC hIPSC core facility benefits from state of the art environment for stem cell research and also from the broad expertise of research groups on the Addenbrookes Biomedical Campus.